86391-68-6

Usage

InChI:InChI=1/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8-,10+/m1/s1

Upstream product

• 99394-52-2 (E)-5-(2-carboxyvinyl)uridine 
• 1024-99-3 5-iodouridine 
• 58931-19-4 methyl 3-(5-uridinyl)propenoate 
• 58-96-8 uridine 

Relevant academic research and scientific papers

Sulfur-containing uridine anticancer compound and intermediate and preparation method thereof

The invention relates to a 4-sulfur-5-(2-halogenated vinyl)uridine compound which has the higher sensibility to UVA light and the anticancer activity and an intermediate and a preparation method of the compound. The method comprises the following steps that an iodination reaction is performed, a halogenating reaction is performed, hydroxyl on a sugar ring is protected, oxygen is replaced by sulfur, an O protection group is removed, and then 4-sulfur-5-(2-halogenated vinyl)uridine is obtained. The method has the advantages of being short in reaction time and high in yield and product purity, and the defects that in a traditional synthesis method, time and energy are consumed, and the yield is low are overcome. Beneficial conditions are supplied for further developing sulfur-containing nucleoside drugs.

THE SYNTHESIS AND ANTIVIRAL PROPERTIES OF (E)-5-(2-BROMOVINYL)-2'-DEOXYURIDINE-RELATED COMPOUNDS

A method for the synthesis of the potent anti-herpes agent, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) (1) is described.A trace bye-product of the synthesis has been identified as 5-(1,2-dibromo-2-succinimidoethyl)-2'-deoxyuridine (5).A similar bye-product, 5-(1,2-dibromo-2-succinimidoethyl)uridine (4) is formed during the synthesis of (E)-5-(2-bromovinyl)uridine (3).The following derivatives of BVDU have been synthesised: 3'-O-methyl (8), 3-methyl (9), 4-O-ethyl (11), O2,5'-anhydro-(E)-5-(2-bromovinyl)-2'-deoxyuridine (13) and (E)-5-(2-bromovinyl)-2'-deoxyisocytidine (15).Whereas compounds 8, 9 and 15 showed little, if any, antiviral activity, 11 and, in particular, 13, were significantly active against herpes simplex virus type 1 and varicella-zoster virus.

Synthesis and Antiviral Activity of (E)-5-(2-Bromovinyl)uracil and (E)-5-(2-Bromovinyl)uridine

(E)-5-(2-Bromovinyl)uracil (BVU) and (E)-5-(2-bromovinyl)uridine (BVRU) were synthesized starting from 5-formyluracil via (E)-5-(2-carboxyvinyl)uracil or starting from 5-iodouridine via (E)-5-(2-carbomethoxyvinyl)uridine and (E)-5-(2-carboxyvinyl)uridine, respectively.Depending on the choice of the cell system, BVU and BVRU exhibited a marked activity against herpes simplex virus type 1 (HSV-1) in vitro.Although BVU and BVRU were less potent than the reference compound (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), their antiviral activity spectrum was remarkably similar to that of BVDU.The latter findings suggest that BVU and BVRU are metabolically converted to BVDU or a phosphorylated product thereof.In vivo, BVU protected mice against a lethal disseminated HSV-1 infection.

Process for the preparation of 5-(2-bromovinyl)-uridine

The invention relates to (E)-5-(2-bromovinyl)-uridine and its derivatives of general formula VI, STR1 wherein R1 stands for a hydrogen atom, C1-8 alkanoyl group, benzoyl group or a benzoyl group substituted in para position either with a C1-4 alkyl group or a halogen atom, and a process for preparing them by brominating 2',3',5'-tri-O-acyl-5-ethyl-uridine of general formula IV, STR2 wherein R is identical with R1, except where R1 stands for a hydrogen atom, dehydrohalogenating the resulting dibromo compound of general formula V STR3 and optionally deacylating it. The resulting compounds of general formula VI are exhibiting significant potency against Herpes simplex virus species and are of remarkably low acute toxicity.